Journal of Infectious Diseases & Therapy
Open Access

Abstract

Atopic dermatitis field is undergoing a translational revolution lately with active development of novel topical and systemic therapeutics. In psoriasis a system biology approach was instrumental in defining biomarkers of disease and therapeutic response as well as predictors of successful response to treatment. We have lately defined a unified atopic dermatitis phenotype using a meta-analysis approach that highlighted key features and biomarkers of atopic dermatitis. This meta-analysis derived transcriptome (MADAD) identified wide lipid abnormalities and for the first time in vivo, correlated Th2 immune activation with down-regulation of key epidermal lipids, emphasizing the role of cytokines on the barrier disruption in AD. MADAD is now applied to evaluate changes with different investigational treatments, allowing us to evaluate drug effect at the transcriptomic level not only on the AD phenotype but also the effect on suppressing specific pathways. Since many aspects of atopic dermatitis are constantly evaluated in various mouse models, we also seek to see how well the commonly used mouse models of atopic dermatitis compare with the human MADAD AD phenotype at the transcriptomic level and which mouse model if any captures the hallmark pathways of AD better.

Biography

Email: mayte.suarezfarinas@mssm.edu